<?xml version="1.0" encoding="UTF-8"?>
<p id="Par6">Presently, there are only two classes of drugs available against different influenza A strains and subtypes licensed by the U.S. Food and Drug Administration (FDA): matrix-2 (M2) protein ion channel blockers (such as amantadine and rimantadine) and neuraminidase (NA) inhibitors (such as zanamivir and oseltamivir) [
 <xref ref-type="bibr" rid="CR7">7</xref>]. However, during the last years, there has been a remarkable increase in the emergence of drug-resistant strains, which have become a major public health concern around the world [
 <xref ref-type="bibr" rid="CR8">8</xref>, 
 <xref ref-type="bibr" rid="CR9">9</xref>]. Therefore, there is a growing need to identify and evaluate alternative anti-influenza agents which exert a different mechanism of action compared with the conventional drugs.
</p>
